LN-145

Phase 2Cell therapy

IIovance Biotherapeutics, Inc.

LN-145 is one of 68 biologic programs targeting Metastatic Non Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Non Small Cell Lung CancerRecruiting

Tumor Infiltrating LymphocytesRecruiting

Squamous Cell CarcinomaRecruiting

Metastatic Non Small Cell Lung CancerPhase 2

Recruiting

Tumor Infiltrating LymphocytesPhase 2

Recruiting

Squamous Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

64 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

59 2

Gilotrif

Boehringer Ingelheim

Approved

10 3

Keytruda

Merck & Co.

Phase 3

19 4

Erbitux

IImclone

Phase 3

45 5

Aliqopa

Bayer Aspirin

Opdivo

14 8

Taxol

Teva

Phase 3

12 9

Tecentriq

Roche

Phase 3

7 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Squamous Cell Carcinoma

NCT07288073

Q3 2029

Phase 2Recruiting

Tumor Infiltrating Lymphocytes

NCT03645928

Q4 2031

Phase 2Recruiting

Metastatic Non Small Cell Lung Cancer

NCT04614103

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma2 trials

TIL Therapy in cSCC and MCC

Recruiting·—·Phase 2·NCT07288073·14 enrolled

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Completed·IIovance Biotherapeutics, Inc.·Phase 2·NCT03083873·64 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Withdrawn·IIovance Biotherapeutics, Inc.·Phase 2·NCT03419559

Tumor Infiltrating Lymphocytes1 trial

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT03645928·245 enrolled

Cervical Carcinoma1 trial

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Terminated·IIovance Biotherapeutics, Inc.·Phase 2·NCT03108495·210 enrolled

Metastatic Non Small Cell Lung Cancer1 trial

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT04614103·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for LN-145. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LN-145 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LN-145. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Iovance Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: IIovance Biotherapeutics, Inc.

LN-145

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Q4 2031

Trials by Indication[1]

Squamous Cell Carcinoma2 trials

Non-Small Cell Lung Cancer1 trial

Tumor Infiltrating Lymphocytes1 trial

Cervical Carcinoma1 trial

Metastatic Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News